Mr. Tao has over 25 years of experience practicing law in the PRC, focusing on debt and equity financing by PRC companies in both domestic and overseas markets, including advising issuers, underwriters and investors in connection with IPO and listing on Shanghai Stock Exchange (Main Board and STAR Market), Shenzhen Stock Exchange (Main Board and ChiNext), HKEX, NYSE and NASDAQ, and post-listing restructuring, mergers and acquisitions, take-private and re-listing transactions.
Mr. Tao’s most recent representative deals include: (a) acting as the issuer’s counsel to Amlogic (Shanghai) (2019), Suzhou Zelgen Biopharmaceuticals (2020) Chengdu-based HitGen (2020) and Hinova Pharma (2022), in their initial public offering and listing on the STAR Market of Shanghai Stock Exchange; (b) acting as the underwriters’ PRC counsel to BeiGene in its initial public offering and listing on the STAR Market of Shanghai Stock Exchange in 2021; (b) acting as the underwriter’s PRC counsel to Microport Robotics (2021), New Horizon (2021), Vensyc (2020) in their initial public offering and listing on HKEX, and acting as the issuer’s PRC counsel to Vivo Biotech in its initial public offering and listing on HKEX (2019); (c) acting as the underwriter’s PRC counsel to Dingdong in its initial public offering and listing on NYSE in 2021; and (d) representing NASDAQ and Madrid-listed Grifols S.A. in its cross-border share swap with Shenzhen-listed SH RAAS in 2020, etc.
Mr. Tao has been selected as “Leading Lawyer” in capital market and mergers and acquisitions areas by Asialaw and IFLR since 2012. He is also ranked as a “Recommended Lawyer” by Chambers in corporate and commercial area (Band I) and a “Stand-out Lawyers” by Thomson Reuters in 2021.
B.A., Shandong Normal University, 1991
LL.M. East China University of Politics and Law, 2000
Member of the All China Bar Association
Chambers Greater China Region 2022